Total submissions: 14
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Clin |
RCV000148501 | SCV003762191 | uncertain significance | Marfan syndrome | 2022-12-01 | reviewed by expert panel | curation | The NM_000138 c.59A>G, is a missense variant in FBN1 predicted to cause a substitution of a Tyrosine by a Cysteine at amino acid 20 (p.Tyr20Cys). This variant was found in a proband with aortic root dilatation and a systemic score of 7 or above which is a highly specific phenotype for Marfan syndrome, however, a pathogenic splice variant in FBN1 was also identified in cis in this individual (BP2). The variant segregates with the disease in 4 affected family members, who also carry the pathogenic splice variant in FBN1. The variant in FBN1 has been reported 12 times in ClinVar: 3 times as likely benign, 8 times as uncertain significance and once as likely pathogenic (Variation ID: 161245). This variant has been identified in 37 individuals of European non-Finnish origin (MAF: 0.029%) (BS1; https://gnomad.broadinstitute.org/ version 2.1.1). The constraint z-score for missense variants affecting FBN1 is 5.06, however due to the presence of two benign arguments, PP2 cannot be used. In summary, this variant meets criteria to be classified as likely benign for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: BS1, BP2 |
| Eurofins Ntd Llc |
RCV000587403 | SCV000227023 | uncertain significance | not provided | 2015-01-09 | criteria provided, single submitter | clinical testing | |
| Gene |
RCV000587403 | SCV000233704 | uncertain significance | not provided | 2024-11-19 | criteria provided, single submitter | clinical testing | Does not affect a cysteine residue within a calcium-binding EGF-like domain of the FBN1 gene; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (PMID: 12938084); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25812041, 25637381, 26017485, 16222657, 24941995, 29543232, 12938084) |
| Laboratory for Molecular Medicine, |
RCV000181402 | SCV000539151 | uncertain significance | not specified | 2016-03-31 | criteria provided, single submitter | clinical testing | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Multiple papers report as VUS; ExAC: 16/66648 Europeans; ClinVar: 1 LB, 2 VUS |
| Labcorp Genetics |
RCV000545272 | SCV000627947 | likely benign | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2025-01-07 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000181402 | SCV000695575 | likely benign | not specified | 2024-11-29 | criteria provided, single submitter | clinical testing | Variant summary: FBN1 c.59A>G (p.Tyr20Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00015 in 251386 control chromosomes. The observed variant frequency is approximately 1.31 fold of the estimated maximal expected allele frequency for a pathogenic variant in FBN1 causing Marfan Syndrome phenotype (0.00011). This variant has been reported in multiple affected individuals without strong evidence for causality. Although, one paper, Yang_2014 indicates the variant does segregate with disease in the family, however, clinical information is not provided for additional family members. The following publications have been ascertained in the context of this evaluation (PMID: 16222657, 24941995, 26017485). ClinVar contains an entry for this variant (Variation ID: 161245). Based on the evidence outlined above, the variant was classified as likely benign. |
| Ce |
RCV000587403 | SCV001149473 | uncertain significance | not provided | 2016-05-01 | criteria provided, single submitter | clinical testing | |
| Color Diagnostics, |
RCV000604732 | SCV001349837 | likely benign | Familial thoracic aortic aneurysm and aortic dissection | 2020-01-06 | criteria provided, single submitter | clinical testing | |
| CHEO Genetics Diagnostic Laboratory, |
RCV000604732 | SCV002042005 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2022-07-22 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV000604732 | SCV002657151 | likely benign | Familial thoracic aortic aneurysm and aortic dissection | 2025-02-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| CSER _CC_NCGL, |
RCV000148501 | SCV000190210 | uncertain significance | Marfan syndrome | 2014-06-01 | no assertion criteria provided | research | |
| Centre for Genomic and Experimental Medicine, |
RCV000604732 | SCV000731233 | likely pathogenic | Familial thoracic aortic aneurysm and aortic dissection | no assertion criteria provided | research | ||
| Diagnostic Laboratory, |
RCV000587403 | SCV001740151 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
| Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000587403 | SCV001964116 | uncertain significance | not provided | no assertion criteria provided | clinical testing |